Stephens Investment Management Group LLC Has $57.44 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Stephens Investment Management Group LLC increased its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 19.5% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 841,084 shares of the medical device company's stock after acquiring an additional 137,165 shares during the quarter. Stephens Investment Management Group LLC owned approximately 0.21% of DexCom worth $57,438,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. Golden State Wealth Management LLC raised its stake in DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after buying an additional 264 shares in the last quarter. Optiver Holding B.V. bought a new position in DexCom in the 4th quarter worth approximately $33,000. TD Private Client Wealth LLC boosted its stake in DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after purchasing an additional 167 shares in the last quarter. Heck Capital Advisors LLC bought a new position in DexCom during the 4th quarter valued at $38,000. Finally, Alpine Bank Wealth Management acquired a new stake in shares of DexCom during the 1st quarter valued at $40,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Buying and Selling

In related news, EVP Michael Jon Brown sold 500 shares of the business's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $82.80, for a total transaction of $41,400.00. Following the transaction, the executive vice president directly owned 95,102 shares in the company, valued at approximately $7,874,445.60. The trade was a 0.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Nicholas Augustinos sold 3,672 shares of the business's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $82.80, for a total value of $304,041.60. Following the transaction, the director directly owned 33,411 shares in the company, valued at approximately $2,766,430.80. This trade represents a 9.90% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 27,190 shares of company stock worth $2,281,732 in the last three months. Insiders own 0.32% of the company's stock.

Analysts Set New Price Targets

DXCM has been the subject of several recent analyst reports. Canaccord Genuity Group raised their target price on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Wall Street Zen cut shares of DexCom from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Robert W. Baird dropped their price objective on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. The Goldman Sachs Group began coverage on DexCom in a report on Friday, May 30th. They set a "buy" rating and a $104.00 price objective on the stock. Finally, Truist Financial began coverage on shares of DexCom in a research report on Monday, June 16th. They issued a "buy" rating and a $102.00 price target for the company. Five equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $98.50.

DexCom Stock Up 2.4%

Shares of DXCM traded up $1.96 during midday trading on Monday, hitting $85.33. The stock had a trading volume of 2,364,860 shares, compared to its average volume of 4,425,556. The company has a 50 day simple moving average of $84.35 and a two-hundred day simple moving average of $79.99. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $117.19. The firm has a market cap of $33.46 billion, a price-to-earnings ratio of 63.68, a price-to-earnings-growth ratio of 1.78 and a beta of 1.44. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The firm had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same period in the prior year, the business posted $0.32 EPS. The firm's quarterly revenue was up 12.5% compared to the same quarter last year. On average, analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.